Join our daily newsletter At The Bell to receive exclusive market insights
- Antisense Therapeutics (ANP) has raised just under $2.6 million from an entitlement offer which will be used for clinical research trials in Europe
- The company received applications from eligible shareholders for about 10.8 million shares at an issue price of 24 cents
- With a previous placement completed in November, the company has raised a total of about $22.6 million from capital raising
- Shares are trading 2.63 per cent lower this morning at 18.5 cents per share
Antisense Therapeutics (ANP) has raised just under $2.6 million from an entitlement offer that will be used for clinical research trials in Europe.
The entitlement offer was one share for 9.4 pro-rata non-renounceable offer, plus one attaching unlisted option for every two shares issued.
The company received applications for about 10.8 million new shares from eligible shareholders. Shares were issued on the same terms as the previous placement at 24 cents each.
With the previous placement, a total of $22.6 million has been received in gross funds from capital raising.
The funds will be used for the preparation and initiation of the company’s clinical research trials for Muscular Dystrophy in Europe. It will be utilised for Phase 2b/3 trials of ATL1102.
Shares were trading 1.32 per cent lower this morning at 18.8 cents per share at 12.20 am AEDT.
